Search Results - "Almudhfar, Niran"

Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits by Frankel, Nicholas W., Deng, Han, Yucel, Gozde, Gainer, Marcus, Leemans, Nelia, Lam, Alice, Li, Yongshuai, Hung, Michelle, Lee, Derrick, Lee, Chen-Ting, Banicki, Andrew, Tian, Mengxi, Almudhfar, Niran, Naitmazi, Lawrence, Roguev, Assen, Lee, Seunghee, Wong, Wilson, Gordley, Russell, Lu, Timothy K., Garrison, Brian S.

“…Acute myeloid leukemia (AML) is an aggressive disease with a poor prognosis (5-year survival rate of 30.5% in the United States). Designing cell therapies to…”
Get full text

257 NOT gate gene circuits expand the range of tumor-associated antigens addressable by CAR-NK and -T cell therapies by Frankel, Nicholas W, Roguev, Assen, Gainer, Marcus, Caradonna, Ippolito I, Hua, Tony, Deng, Han, Yucel, Gozde, Lam, Alice, Li, Yongshuai, Hung, Michelle, Lee, Derrick, Lee, Chen-Ting, Banicki, Andrew, Tian, Mengxi, Almudhfar, Niran, Naitmazi, Lawrence, Gordley, Russell M, Garrison, Brian, Rajangam, Kanya, Lu, Timothy K

“…BackgroundChimeric antigen receptors (CARs) can direct immune cells, such as T or NK cells, to kill cancer cells expressing a tumor-associated antigen (TAA)…”
Get full text

116 Development of logic gated CAR-NK cells for the treatment of solid tumors by Junca, Alba Gonzalez, Frankel, Nicholas, Gainer, Marcus, Mullenix, Alyssa, Palermo, Miguel, Lee, Derrick, Liu, Frances, Gordley, Russell, Lee, Chen-Ting, Roguev, Assen, Almudhfar, Niran, Tian, Mengxi, Lee, Gary

“…BackgroundCAR-based therapies have transformed the treatment of several cancers, but this progress has not translated into solid tumors. One challenge of…”
Get full text

SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors by Gonzalez-Junca, Alba, Liu, Frances D, Nagaraja, Archana S, Mullenix, Alyssa, Lee, Chen-Ting, Gordley, Russell M, Frimannsson, Daniel O, Maller, Ori, Garrison, Brian S, Iyer, Dharini, Benabbas, Anissa, Truong, Tiffany A, Quach, Allison, Tian, Mengxi, Martinez, Rowena, Savur, Rishi, Perry-McNamara, Alyssa, Nguyen, Denny, Almudhfar, Niran, Blanco, Carmina, Huynh, Christina, Nand, Asish, Lay, Yu-An E, Magal, Ashita, Mangalampalli, Sravani, Lee, Philip J, Lu, Timothy K, Lee, Gary

“…Advanced peritoneal carcinomatosis including high-grade ovarian cancer has poor prognoses and a poor response rate to current checkpoint inhibitor…”
Get full text

Abstract 1333: Preclinical data supporting the Phase 1 trial design of SENTI-202, a next generation allogeneic logic-gated selective CAR NK cell therapy, engineered to overcome key limitations of first generation cell therapies in AML by Kaveri, Deepika, Chinta, Pearley, Leitner, Elizabeth, Naitmazi, Lawrence, Yucel, Gozde, Tian, Mengxi, Almudhfar, Niran, Deng, Han, Li, Yongshuai, Lam, Alice, Lee, Chen-Ting, Hong, Enping, Emery, Rochelle, Garrison, Brian, Nguyen, Aaron N., Rajangam, Kanya

“…Abstract First generation natural killer (NK) and chimeric antigen receptor (CAR) NK cell products are well-tolerated and have clinical activity (~20-60% CR)…”
Get full text

Abstract 2902: Off-the-Shelf CAR-NK cells engineered to express calibrated release IL-15 exhibit enhanced persistence and anti-tumor activities by Lee, Chen-Ting, Hung, Michelle, Banicki, Andrew, Song, Wenqi, Almudhfar, Niran, Kaveri, Deepika, Wong, Priscilla, Naitmazi, Lawrence, Guzman, Marcela, Lam, Alice, Yucel, Gozde, Lu, Timothy, Junca, Alba G., Garrison, Brian, Lee, Philip

“…Abstract Chimeric antigen receptor (CAR) natural killer (NK) cell therapy is an attractive immunotherapy strategy due to potential for increased anti-tumor…”
Get full text

Abstract 2905: SENTI-301A, an off-the-shelf multi-armed preclinical CAR-NK cell therapy, for the treatment of GPC3 expressing tumors by Ayala, Marcela Guzman, Kaveri, Deepika, Hong, Enping, Leitner, Elizabeth, Wong, Priscilla, Ponek, Ronni, Naitmazi, Lawrence, Chinta, Pearley, Gorman, Wesley, Tian, Mengxi, Almudhfar, Niran, Lee, Kelly, Frankel, Nicholas, Junca, Alba Gonzalez, Gordley, Russell, Lee, Philip, Lu, Timothy, Rajangam, Kanya

“…Abstract Purpose: SENTI-301A is a novel off-the-shelf CAR-NK product candidate that uses gene circuits to enhance NK cell persistence and targeted cytotoxicity…”
Get full text

Abstract 3195: Preclinical development of SENTI-202, an off-the-shelf logic gated CAR-NK cell therapy, for the treatment of CD33/FLT3+ hematologic malignancies including AML by Gonzalez, Alba, Hong, Enping, Yucel, Gozde, Leitner, Elizabeth, Chinta, Pearley, Deng, Han, Li, Ian, Lam, Alice, Bakir, Abla, Lee, Brandon, Chakraborty, Papia, Blanco, Carmina, Lee, Chen-Ting, Almudhfar, Niran, Tian, Mengxi, Song, Wenqi, Banicki, Andrew, Contreras, Otto, Gieldin, Martin, Garrison, Brian, Lu, Timothy K., Rajangam, Kanya

“…Abstract CD33 and FLT3 are validated targets for myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These…”
Get full text